Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet.

Company
R&D
Product
Investors
Sustainability
Media
Careers

DW WAY
History
Global Network
Affiliated Companies
Contact Point

R&D Centers
R&D Projects
Achievements

Biologics
Chemicals
CTD LIST

IR Highlights
Financial Info
Stock Info
IR

Sustainability Report
Compliance Program
Corporate Governance

News
Brand Resource

Company

DW WAY
History
Global Network
Affiliated Companies
Contact Point

R&D

R&D Centers
R&D Projects
Achievements
- Research Performance
- Platform Technology

Product

Biologics
Chemicals
CTD LIST

Investors

IR Highlights
Financial Info
Stock Info
IR

Sustainability

Sustainability Report
Compliance Program
Corporate Governance

Media

News
Brand Resource

CEO
Chang-jae Lee, Seongsoo Park
Address
Bongeunsa-ro 114-gil 12, Gangnam-gu, Seoul, Korea
Corporate Registration Number
124-86-01143

Company
DW WAY
History
Global Network
Affiliated Companies
Contact Point

R&D
R&D Centers
R&D Projects
Achievements

Product
Biologics
Chemicals
CTD LIST

Investors
IR Highlights
Financial Info
Stock Info
IR

Sustainability
Sustainability Report
Compliance Program
Corporate Governance

Media
News
Brand Resource

Careers

Privacy Policy Terms of Use

Copyright 2025 DAEWOONG PHARMACEUTICAL CO.,LTD.
All rights reserved.

Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet.